"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the ...

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

Danish maker of obesity drugs to replace Lars Fruergaard Jørgensen, saying new leadership is needed as shares slump 50% in ...

Lars Fruergaard Jørgensen, the chief executive of once-highflying Danish drug manufacturer Novo Nordisk, is stepping down after eight years in the role, the maker of the drugs Ozempic and Wegovy ...

Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains ...

Lars Fruergaard Jørgensen, who has led the pharmaceutical giant since 2017, joined the firm in 1991.View on euronews ...

Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down following a plunge in the company's share price ...

For decades, the snack and beverage category has been dominated by companies that specialize in making delicious foods. Many ...

BENGALURU (Reuters) -U.S.-based Waters Corp, which makes medical equipment used in clinical testing, has seen a spurt in ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...